drugset / Trial / NCT04575896
Kidney Transplants in Hepatitis C Negative Recipients With Hepatitis C Viremic Donors
NaSingle-groupOpen-labelTreatment
Summary
In this study, individuals without hepatitis C infection who are on the kidney transplant waitlist will receive a kidney from a deceased donor with hepatitis C infection and will be treated for hepatitis C at the same time. Treatment will include glecaprevir 300 mg / pibrentasvir 120 mg (G-P) administered on-call to the operating room for the renal transplant procedure and continued for 2 weeks post-renal transplant.
Timeline
- Start
- 2020-11-20
- Primary completion
- 2023-11-28
- Completion
- 2023-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | glecaprevir | Other / unclassified | 300 mg | Oral |
| Subject | pibrentasvir | Other / unclassified | 120 mg | Oral |